Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IntReALL BCP 2020 for childhood relapsed precursor B-cell ALL
2023-509392-17-00Phase 3Authorised
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of blinatumomab and inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL) (6 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Event-free survival and Disease-free survival. Planned start Mar 2026; status: authorised.
02
Drugs
blinatumomabinotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2023-509392-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509392-17-00.